Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling.

Bili Wang, Can Shen, Yang Li, Ting Zhang, Hui Huang, Jun Ren, Zhengjun Hu, Jian Xu, Bin Xu
Author Information
  1. Bili Wang: Department of Clinical Laboratory, Medical Technology College, Zhejiang Chinese Medical University, Hangzhou 310053, People's Republic of China.
  2. Can Shen: Department of Clinical Laboratory, Medical Technology College, Zhejiang Chinese Medical University, Hangzhou 310053, People's Republic of China.
  3. Yang Li: Department of Clinical Laboratory, Medical Technology College, Zhejiang Chinese Medical University, Hangzhou 310053, People's Republic of China.
  4. Ting Zhang: Department of Clinical Laboratory, Medical Technology College, Zhejiang Chinese Medical University, Hangzhou 310053, People's Republic of China.
  5. Hui Huang: Department of Clinical Laboratory, Medical Technology College, Zhejiang Chinese Medical University, Hangzhou 310053, People's Republic of China.
  6. Jun Ren: Department of Clinical Laboratory, Medical Technology College, Zhejiang Chinese Medical University, Hangzhou 310053, People's Republic of China.
  7. Zhengjun Hu: Department of Clinical Laboratory, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, People's Republic of China.
  8. Jian Xu: Department of Clinical Laboratory, Medical Technology College, Zhejiang Chinese Medical University, Hangzhou 310053, People's Republic of China.
  9. Bin Xu: Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, People's Republic of China.

Abstract

Chemotherapy remains a primary treatment method for advanced pancreatic cancer. However, chemotherapy resistance can influence the therapeutic effect of pancreatic cancer. The resistance mechanism of chemotherapeutic agents such as gemcitabine, which is an agent typically used to treat pancreatic cancer, is complicated and can be influenced by genes and the environment. Oridonin is a tetracyclic diterpenoid compound extracted from the traditional Chinese herb . Oridonin may overcome drug resistance in pancreatic cancer, but researching pancreatic cancer drug resistance of chemotherapy by oridonin is not completely understood. The present study aimed to assess the impact of oridonin on multidrug resistance proteins, apoptosis-associated proteins and energy metabolism in gemcitabine-resistant PANC-1 (PANC-1/Gem) pancreatic cancer cells. Gemcitabine resistance in PANC-1/Gem cells was induced using a concentration gradient of gemcitabine. Cell Counting Kit-8 assays were used to detect the impact of gemcitabine and oridonin on the proliferation of PANC-1 and PANC-1/Gem cells. Western blot analysis and immunofluorescence were used to detect the expression of multidrug resistance proteins, apoptosis-associated proteins and low-density lipoprotein receptor protein 1 (LRP1) proteins in PANC-1/Gem cells. The effects of gemcitabine and oridonin on PANC-1/Gem cells apoptosis were detected using flow cytometry. Animal xenograft tumor assays were used to detect the effect of gemcitabine and oridonin on pancreatic cancer in vivo. Furthermore, the ATP Assay kit was used to determine the effects of gemcitabine and oridonin on ATP levels in PANC-1/Gem cells. Immunofluorescence assays were used to detect the effects of gemcitabine and oridonin on the expression of low-density lipoprotein receptor protein 1 (LRP1) in PANC-1/Gem cells. In addition, LRP1 expression was knocked down in PANC-1/Gem cells via lentiviral vector-mediated RNA silencing. Clone formation assays and Western blot analysis were used to detect the effect of LRP1 knockdown on the proliferation of PANC-1/Gem cells. The present results demonstrate that oridonin overcomes PANC-1/Gem cells gemcitabine reistance by regulating GST pi and LRP1/ERK/JNK signaling. In conclusion, the present study indicated that oridonin could overcome gemcitabine resistance in PANC-1/Gem cells by regulating GST pi and LRP1/ ERK/JNK signaling, inducing cell apoptosis. Therefore, oridonin with gemcitabine may be a promising preoperative treatment for patients who suffer from pancreatic cancer.

Keywords

References

  1. Cancer. 2000 Oct 1;89(7):1440-7 [PMID: 11013356]
  2. Curr Opin Genet Dev. 2002 Feb;12(1):14-21 [PMID: 11790549]
  3. Biochem Biophys Res Commun. 2002 Apr 26;293(1):598-601 [PMID: 12054644]
  4. Int J Cancer. 2006 Nov 1;119(9):2155-64 [PMID: 16823842]
  5. Anticancer Res. 2007 Jul-Aug;27(4B):2115-20 [PMID: 17695494]
  6. J Clin Invest. 2008 Dec;118(12):3943-53 [PMID: 19033664]
  7. Pancreatology. 2009;9(1-2):136-44 [PMID: 19077464]
  8. Science. 2009 Jun 12;324(5933):1457-61 [PMID: 19460966]
  9. J Clin Oncol. 2009 Aug 10;27(23):3778-85 [PMID: 19581537]
  10. PLoS One. 2010 Jul 14;5(7):e11584 [PMID: 20644732]
  11. Neoplasia. 2010 Sep;12(9):740-7 [PMID: 20824050]
  12. Exp Hematol. 2011 May;39(5):558-69 [PMID: 21300134]
  13. Oncol Rep. 2011 Nov;26(5):1081-9 [PMID: 21805041]
  14. Int J Oncol. 2012 Apr;40(4):1049-57 [PMID: 22159556]
  15. J Gastrointest Surg. 2012 Jul;16(7):1333-40 [PMID: 22618517]
  16. J BUON. 2012 Apr-Jun;17(2):284-90 [PMID: 22740207]
  17. Cancer Biol Ther. 2012 Nov;13(13):1244-54 [PMID: 22895079]
  18. PLoS One. 2012;7(12):e50786 [PMID: 23226540]
  19. Cancer Lett. 2013 Jun 1;333(1):89-95 [PMID: 23348695]
  20. Annu Rev Phytopathol. 2013;51:245-66 [PMID: 23663002]
  21. PLoS One. 2013 Jun 24;8(6):e67589 [PMID: 23826324]
  22. J Clin Invest. 2014 Apr;124(4):1525-36 [PMID: 24614108]
  23. World J Gastroenterol. 2014 Oct 28;20(40):14895-903 [PMID: 25356049]
  24. J Integr Med. 2014 Nov;12(6):483-94 [PMID: 25412666]
  25. Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2473-8 [PMID: 25675507]
  26. J Biomed Res. 2015 Apr;29(2):132-8 [PMID: 25859268]
  27. World J Surg Oncol. 2015 Feb 21;13:66 [PMID: 25880226]
  28. Biochim Biophys Acta. 2015 Aug;1856(1):13-27 [PMID: 25977074]
  29. J Pineal Res. 2016 Jan;60(1):27-38 [PMID: 26445000]
  30. World J Surg Oncol. 2016 Feb 29;14:59 [PMID: 26927942]
  31. Ann Transl Med. 2016 May;4(9):165 [PMID: 27275478]
  32. Oncotarget. 2016 Aug 2;7(31):50117-50130 [PMID: 27367026]
  33. Int J Oncol. 2017 Jan;50(1):111-120 [PMID: 27878247]
  34. Cell Death Dis. 2017 Feb 23;8(2):e2633 [PMID: 28230866]
  35. Cancer Manag Res. 2017 Apr 21;9:141-148 [PMID: 28461766]
  36. Crit Rev Oncol Hematol. 2017 Jun;114:139-152 [PMID: 28477742]
  37. J Integr Med. 2017 Jul;15(4):282-287 [PMID: 28659232]
  38. Cancer Cell. 2017 Jul 10;32(1):71-87.e7 [PMID: 28697344]
  39. Cancer Res. 2017 Oct 15;77(20):5503-5517 [PMID: 28811332]
  40. J Integr Med. 2017 Nov;15(6):469-475 [PMID: 29103417]
  41. J Clin Oncol. 1997 Jun;15(6):2403-13 [PMID: 9196156]

Word Cloud

Created with Highcharts 10.0.0cellsgemcitabinePANC-1/GemoridoninpancreaticcancerresistanceusedproteinsdetectassaysLRP1pieffectpresentPANC-1expressionlipoproteinreceptoreffectsregulatingGSTtreatmentchemotherapycanOridoninmayovercomedrugstudyimpactmultidrugapoptosis-associatedusingproliferationWesternblotanalysislow-densityprotein1apoptosisATPovercomessignalingERK/JNKChemotherapyremainsprimarymethodadvancedHoweverinfluencetherapeuticmechanismchemotherapeuticagentsagenttypicallytreatcomplicatedinfluencedgenesenvironment OridonintetracyclicditerpenoidcompoundextractedtraditionalChineseherbresearchingcompletelyunderstoodaimedassessenergymetabolismgemcitabine-resistantGemcitabineinducedconcentrationgradientCellCountingKit-8immunofluorescencedetectedflowcytometryAnimalxenografttumorvivoFurthermoreAssaykitdeterminelevelsImmunofluorescenceadditionknockedvialentiviralvector-mediatedRNAsilencingCloneformationknockdownresultsdemonstratereistanceLRP1/ERK/JNKconclusionindicatedLRP1/inducingcellThereforepromisingpreoperativepatientssufferresistantLRP/1signallingglutathioneS-transferaselowdensity

Similar Articles

Cited By